ArticleArchives of medical sciences. Atherosclerotic diseases2025
Omecamtiv mecarbil, a cardiac myosin activator with potential efficacy in heart failure.
Article in Archives of medical sciences. Atherosclerotic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Troponin: biology, molecular mechanisms, and multidimensional clinical applications.Molecular biomedicine · 2026Review
- The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure.Biomedicines · 2026Review
- FHOD3 deficiency disrupts sarcomere organization and activates caMKII signaling in human stem cell-derived cardiomyocytes.Stem cell research & therapy · 2026Article
- Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a growing global epidemic resulting in significant morbidity and mortality. The pathophysiology of HF with reduced ejection fraction (HFrEF) is characterized by impaired systolic function resulting in diminished cardiac output. A new class of inotropes, cardiac myosin activators were developed to directly augment cardiac sarcomere function and improve myocardial activity in HFrEF. The first drug in this class, omecamtiv mecarbil selectively activates cardiac myosin and improves cardiac contractility by increasing the efficiency of the actin-myosin cross-bridge cycle, increasing the duration of systolic ejection without raising myocardial oxygen demand. The first major trial investigating omecamtiv mecarbil use in HFrEF demonstrated a statistically significant decrease in the composite endpoint of the first HF event or death from cardiovascular causes. A post hoc analysis demonstrated that omecamtiv mecarbil produced a statistically significant reduction in the composite endpoint of time to the first HF event or cardiovascular death among patients with severe HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.